{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:30:31Z","timestamp":1757309431631,"version":"3.37.3"},"reference-count":23,"publisher":"The Journal of Rheumatology","issue":"Suppl 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2024,7,1]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>Psoriasis (PsO) is commonly classified as mild, moderate, or severe, usually based on body surface area (BSA) or other validated measures. Although most dermatologists agree that mild PsO should be treated with topical therapies, there are circumstances where mild or limited PsO should be treated with biologics, even as first line. A debate about use of topical vs biologic therapy was presented at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 annual meeting. Arguments in favor of using biologics when patients have mild disease on limited BSA included presence of psoriatic arthritis (PsA) and symptoms on special sites (ie, scalp, face, body folds, genitals, nails, palms, soles). New data suggest that treating limited or early PsO may decrease the risk of developing PsA. Arguments against using biologics for mild PsO focused on the definition of mild PsO, citing that limited BSA with PsA and significant quality of life impact should not be defined as mild. Truly mild PsO should be treated with topical agents, given their safety and relative low cost. The availability of newer agents like roflumilast and tapinarof have expanded therapeutic choice and have data supporting their use for treatment of special sites.<\/jats:p>","DOI":"10.3899\/jrheum.2024-0655","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T12:25:35Z","timestamp":1722515135000},"page":"39-42","source":"Crossref","is-referenced-by-count":1,"title":["GRAPPA Point-Counterpoint: Should Biologics Be Used for Mild Psoriasis?"],"prefix":"10.3899","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8254-9129","authenticated-orcid":false,"given":"Gretchen D.","family":"Ball","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1768-6808","authenticated-orcid":false,"given":"Hassan","family":"Hamade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2927-8618","authenticated-orcid":false,"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7596-892X","authenticated-orcid":false,"given":"Brian","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-0439","authenticated-orcid":false,"given":"Kristina Callis","family":"Duffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"2024120403401490000_51.Suppl_2.39.1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3390\/life11070627","article-title":"A new classification of the severity of psoriasis: what\u2019s moderate psoriasis?","volume":"11","author":"Salgado-Boquete","year":"2021","journal-title":"Life"},{"key":"2024120403401490000_51.Suppl_2.39.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.11.055"},{"key":"2024120403401490000_51.Suppl_2.39.3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4103\/ijd.ijd_420_23","article-title":"Disease assessment in psoriasis","volume":"68","author":"Manchanda","year":"2023","journal-title":"Indian J Dermatol"},{"key":"2024120403401490000_51.Suppl_2.39.4","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","article-title":"Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011","volume":"149","author":"Armstrong","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2024120403401490000_51.Suppl_2.39.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204858"},{"key":"2024120403401490000_51.Suppl_2.39.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"2024120403401490000_51.Suppl_2.39.7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/art.41946","article-title":"Incidence of psoriatic arthritis among patients receiving biologic treatments for psoriasis: a nested case-control study","volume":"74","author":"Rosenthal","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2024120403401490000_51.Suppl_2.39.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220865"},{"key":"2024120403401490000_51.Suppl_2.39.9","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)01479-8"},{"key":"2024120403401490000_51.Suppl_2.39.10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s13555-017-0207-0","article-title":"The efficacy of biologic therapy for the management of palmoplantar psoriasis and palmoplantar pustulosis: a systematic review","volume":"7","author":"Sanchez","year":"2017","journal-title":"Dermatol Ther"},{"key":"2024120403401490000_51.Suppl_2.39.11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","article-title":"Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council","volume":"82","author":"Strober","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024120403401490000_51.Suppl_2.39.12","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/jamadermatol.2023.1338","article-title":"Biosimilars for the treatment of psoriasis: a systematic review of clinical trials and observational studies","volume":"159","author":"Phan","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2024120403401490000_51.Suppl_2.39.13","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2022.15632","article-title":"Effect of Roflumilast cream vs vehicle cream on chronic plaque psoriasis: the DERMIS-1 and DERMIS-2 randomized clinical trials","volume":"328","author":"Lebwohl","year":"2022","journal-title":"JAMA"},{"key":"2024120403401490000_51.Suppl_2.39.14","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2103629","article-title":"Phase 3 trials of tapinarof cream for plaque psoriasis","volume":"385","author":"Lebwohl","year":"2021","journal-title":"N Engl J Med"},{"key":"2024120403401490000_51.Suppl_2.39.15","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/j.1365-2133.2010.09985.x","article-title":"Clinical and genetic predictors of response to narrowband ultraviolet B for the treatment of chronic plaque psoriasis","volume":"163","author":"Ryan","year":"2010","journal-title":"Br J Dermatol"},{"key":"2024120403401490000_51.Suppl_2.39.16","first-page":"221","article-title":"Efficacy and safety of apremilast in systemic- and biologic-naive patients with moderate plaque psoriasis: 52-week results of UNVEIL","volume":"17","author":"Stein Gold","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"2024120403401490000_51.Suppl_2.39.17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/jdv.14738","article-title":"Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study","volume":"32","author":"Reich","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024120403401490000_51.Suppl_2.39.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.07.001"},{"key":"2024120403401490000_51.Suppl_2.39.19","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/art.39494","article-title":"The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study","volume":"68","author":"Eder","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2024120403401490000_51.Suppl_2.39.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-219961"},{"key":"2024120403401490000_51.Suppl_2.39.21","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S2665-9913(23)00034-6","article-title":"Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study","volume":"5","author":"Singla","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2024120403401490000_51.Suppl_2.39.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220761"},{"key":"2024120403401490000_51.Suppl_2.39.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-063650"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2024-0655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T11:40:44Z","timestamp":1733312444000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2024-0655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":23,"journal-issue":{"issue":"Suppl 2","published-online":{"date-parts":[[2024,10,1]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.3899\/jrheum.2024-0655"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2024-0655","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"type":"print","value":"0315-162X"},{"type":"electronic","value":"1499-2752"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}